Updated on 27 November 2012
Astellas will collaborate with Nagasaki University and the University of Tokyo for developing treatments for NTDs
Singapore: Furthering its aim to develop new drugs in segments with high unmet need, Japanese company Astellas entered into two collaborations with the Japanese academia in November 2012.
The global R&D company in pharmaceuticals, which seeks to be the global leader in several categories where high unmet medical needs exist and a high degree of expertise is required, has signed collaborative research agreements with Nagasaki University and the University of Tokyo for developing drugs to treat neglected tropical diseases (NTDs).
NTDs, prevalent mainly among the poor in tropical areas of developing countries, are infectious diseases spread by parasites or bacteria. As it is estimated that approximately one billion people are affected with NTDs worldwide, they are a serious healthcare issue that is being addressed on a global scale. Among them, diseases caused by protozoan parasites, such as leishmaniasis, Chagas disease and sleeping sickness are with high unmet medical needs for treatment and development of new therapeutic drugs.
Tie-up with NEKKEN
Under the collaborative agreement with Nagasaki University, the Institute of Tropical Medicine at the university (NEKKEN), which is one of the leading research institutes on tropical infectious diseases in Japan, and Astellas will cooperate on a drug-discovery research project. Astellas will provide multiple compounds with possible anti-protozoan activities, and NEKKEN will evaluate these compounds in experimental model of infection with protozoan parasites for leishmaniasis, Chagas disease and sleeping sickness. The research will be advanced with advice from Professor Kenji Hirayama at NEKKEN, who is a key opinion leader on NTDs research in Japan.
The collaborative research is largely divided into two phases. In the first phase (first screening), the parasiticidal effect of compounds against three species of protozoan parasites will be measured in vitro. In the second phase (second screening), compounds found to be effective for killing protozoan parasites in the first screening will be tested for in vivo activity by evaluating parasitemia and survival rates in animals infected with the protozoan parasites. Organ-specific infection levels will also be measured using a live imaging method.